Trends in Obesity Treatment Show Surge in GLP-1 RAs, Drop in Surgeries

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 29, 2024.

By Lori Solomon HealthDay Reporter

TUESDAY, Oct. 29, 2024 -- Among privately insured patients, there was a doubling in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as antiobesity treatment from 2022 to 2023, with a simultaneous 25.6 percent decrease in the rate of metabolic bariatric surgery, according to a research letter published online Oct. 25 in JAMA Network Open.

Kevin Lin, from Harvard Medical School in Boston, and colleagues assessed national trends and characteristics of patients with obesity who were prescribed GLP-1 RAs versus those undergoing metabolic bariatric surgery. The analysis deidentified claims data from 17 million unique adult patients with obesity and without diabetes with medical and pharmaceutical coverage through commercial and Medicare Advantage insurance.

The researchers identified 81,092 patients who were prescribed GLP-1 RAs (9.6 percent aged 18 to 35 years) and 5,173 patients who underwent metabolic bariatric surgery (17.5 percent aged 18 to 35 years). Greater medical complexity was seen in patients undergoing metabolic bariatric surgery versus those prescribed GLP-1 RAs or no treatment (18.8 versus 8.2 percent versus 11.1 percent with four or more comorbidities). There was a 132.6 percent increase in patients prescribed GLP-1 RAs between the last six months of 2022 and the last six months of 2023 (1.89 versus 4.41 patients per 1,000 patients). Simultaneously, there was a 25.6 percent decrease in patients undergoing metabolic bariatric surgery (0.22 versus 0.16 patients per 1,000 patients).

"Policymakers and clinicians should continue to closely monitor trade-offs between pharmacologic and surgical management of obesity to ensure optimal access to effective obesity treatment," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-10-30 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords